The company’s MAA includes 29 countries using a decentralised procedure (DCP).
Registration in Russia, Turkey and the CIS countries will follow.
Meda CEO Anders Lonner said Acnex is a well documented product that is very effective and well tolerated and will strengthen Meda’s European position in dermatology.